Study on Raludotatug Deruxtecan With or Without Bevacizumab for First-Line Maintenance in Advanced Ovarian Cancer

Inclusion Criteria

• Diagnosed with advanced ovarian cancer (Stage III or IV), fallopian tube cancer, or primary peritoneal cancer.
• Have had surgery to remove as much of the cancer as possible.
• Completed first-line platinum-based chemotherapy with stable disease, partial response, complete response, or no evidence of disease.
• Provided tumor tissue that has not been treated with radiation.
• Recovered from side effects of previous cancer treatments to a mild level or baseline, except for hair loss or skin changes.
• If HIV-positive, must have well-controlled HIV on antiretroviral therapy.

Exclusion Criteria

• Have a type of ovarian cancer that is not high-grade serous or endometrioid.
• Have received first-line chemotherapy without bevacizumab and have stable or partially responding disease at screening.
• Have had other systemic cancer treatments besides the required first-line chemotherapy.
• Not fully recovered from major surgery or have ongoing surgical issues.
• Have a tumor with a specific genetic feature (HRD-positive) or unknown status.
• Have active inflammatory bowel disease needing medication or a history of it.
• Have severe lung issues from other illnesses or past lung surgery.
• Have a bowel obstruction or related issues due to ovarian cancer.
• HIV-positive with a history of certain cancers like Kaposi's sarcoma.
• Have another progressing cancer or one treated in the last 3 years.
• Have an active infection needing treatment.